Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan

https://doi.org/10.17749/2070-4909.2019.12.1.14-26

Full Text:

Abstract

The integrated Model of health care for patients with inflammatory bowel disease (IBD) is based on the creation of specialized centers where multidisciplinary teams provide patient-centered care. Recent studies showed that the introduction of such approach into the IBD treatment practice led to faster diagnosis, an increase in the proportion of patients with mild forms of IBD and, as a result, the reduction of medical costs.
The present study aims to assess the economic consequences of the proposed IBD healthcare optimization in the Republic of Tatarstan.
Materials and methods. A budget impact model was created to compare two scenarios: the basic case when IBD patients are treated according to the current practice based on the existing network of clinics versus the simulated scenario when IBD patients receive medical care within a specialized IBD center, organised in accordance with the integrated multidisciplinary approach. The study hypothesis implies that the proportion of patients with severe IBD is gradually decreasing due to the change in the treatment model and the improved diagnostic procedure. The direct medical costs included the cost of visits to doctors, ambulance calls, diagnostic tests, outpatient medications, and the day-time and 24-hour in-patient care. One-way sensitivity analysis of all model inputs was performed.
Results. As a result of the modified practice in the Republic of Tatarstan, the cost of medical care for IBD patients will decrease by 120 million rubles over 5 years. The sensitivity analysis shows the results are robust and not sensitive to fluctuations in the variables. However, the results are shown to be most sensitive to fluctuations in the distribution of patients by IBD severity.
Conclusion. The introduction of the integrated healthcare for patients with IBD will result in lower costs of this service.

About the Authors

T. P. Bezdenezhnykh
Center for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian Federation; Research Institute of Finance, Ministry of Finance of the Russian Federation
Russian Federation

Tatiana P. Bezdenezhnykh – Leading Specialist, Center for Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation; Junior Researcher at the Center for Healthcare Funding, Financial Research Institute.

Тел.: +7 (495) 783-19-05; доб. 182



D. V. Fedyaev
Center for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian Federation; Research Institute of Finance, Ministry of Finance of the Russian Federation; Russian Presidential Academy of National Economy and Public Administration, Federal State Educational Institution of Higher Professional Education
Russian Federation
Denis V. Fedyaev – Deputy Head of the Department for Methodological Support of Methods of Payment for Medical Aid, Center for Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation, Researcher at the Center for Health Technology Assessment, Russian Presidential Academy of National Economy and Public Administration, Researcher at the Center for Healthcare Funding, Finance Research Institute, Ministry of Finance of RF.


G. R. Khachatryan
Center for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian Federation; Research Institute of Finance, Ministry of Finance of the Russian Federation; Russian Presidential Academy of National Economy and Public Administration, Federal State Educational Institution of Higher Professional Education
Russian Federation
Georgii R. Khachatryan – Head, Department of Methodological Support of Comprehensive HTA, Center for Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation; Researcher at the Laboratory for HTA, Institute of Applied Economic Research of the Presidential Academy; Junior Researcher at the Center for Healthcare Funding, Financial Research Institute.


G. G. Arutyunov
Center for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian Federation
Russian Federation

10-5 Khokhlovskii pereulok, Moscow 109028

Georgii G. Arutyunov – Chief Specialist, Center for Healthcare Quality Assessment and Control, Ministry of Healthcare of the Russian Federation.



K. V. Gerasimova
Center for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian Federation
Russian Federation

10-5 Khokhlovskii pereulok, Moscow 109028

Kseniya V. Gerasimova – PhD, Researcher at the Center for Health Technology Assessment, Applied Economic Research Institute of the Russian Presidential Academy of National Economy and Public Administration.



References

1. Ng S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017; 390 (10114): 2769-2778.

2. Ivashkin V. T., Shelygin Yu. A. et al. Clinical guide of russian association of gastroenterology and russian association of coloproctology on diagnostics and treatment of ulcerative colitis. Koloproktologiya. 2017; 1 (59): 6-30. (in Russ.).

3. Derkach E. V. et al. The Evaluation of Economic Efficiency of Certolizumab Pegol in Patients with Crohn’s Disease. Medicinskie texnologii. Ocenka i vybor. 2016; 3: 19-28. (in Russ.). eLIBRARY ID: 28283209.

4. Zhuravleva M. V. et al. Optimization of drug supply for patients with orphan diseases using foreign experience and the results of the pharmacoeconomic analysis of the “impact on the budget” on the example of ulcerative colitis. Sovremennaya organizaciya lekarstvennogo obespecheniya. 2014; 4 (26): 51-62. (in Russ.).

5. Zyryanov S. K. et al. Impact on the budget of ONLS program of vedolizumab introduction for the treatment of inflammatory bowel disease. Kachestvennaya klinicheskaya praktika. 2017; 4: 45-52. (in Russ.). eLIBRARY ID: 32430994; DOI: 10.24411/2588-0519-2017-00029.

6. Serbina A. A., Veselov A. V. The need to optimize coloproctology service in the Russian Federation. Klinicheskij opyt Dvadcatki. 2014; 4 (24): 49-56. (in Russ.)

7. Trifonova N. Yu., Veselov A. V. High-tech medical aid in the modernization of health care in Russia: the principles and current state. Vestnik Vserossijskogo obshhestva specialistov po medikosocial’noj ehkspertize, reabilitacii i reabilitacionnoj industrii. 2011; 3: 5-7. (in Russ.). eLIBRARY ID: 21669044.

8. Shelygin Yu. A. et al. Main directions of organization of a specialized coloproctological medical care. Koloproktologiya. 2017; 1 (59): 76-81. (in Russ.). eLIBRARY ID: 28298550.

9. Binnatli Sh. A. et al. Quality of life of patients operated on for ulcerative colitis (literature review). Koloproktologiya. 2019; 1 (67): 89-100. (in Russ.).

10. Tkachev A. V. et al. Inflammatory bowel disease: at the intersection of problems. Prakticheskaya medicina. 2012; 3 (58): 17- 22. (in Russ.).

11. Khalif L., Shapina M. V., Golovenko A. O., Belousova Y. A., Chashkova Y. Y., Lakhin A. V., Knyazev O. V., Baranovsky A. Y., Nikolayeva N. N., Tkachev A. V. Chronic inflammatory bowel diseases: the course and treatment methods in Russian Federation (Results of multicenter population-based one-stage observational study). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018; 28 (3): 54-62. (In Russ.) https://doi.org/10.22416/1382-4376-2018-28-3-54-62.

12. Baranovskij A. Yu. et al. A new system of specialized gastroenterological care to patients with inflammatory bowel diseases in Saint Petersburg. Terapevticheskij arxiv (arxiv do 2018 g.). 2013; 85 (2): 17-20. eLIBRARY ID: 1888416ю.

13. Mikocka-Walus A. A. et al. An integrated model of care for inflammatory bowel disease sufferers in Australia: development and the effects of its implementation. Inflammatory bowel diseases. 2011; 18 (8): 1573-1581.

14. van Deen W.K. et al. The impact of value-based healthcare for inflammatory bowel diseases on healthcare utilization: a pilot study. European journal of gastroenterology & hepatology. 2017; 29 (3): 331-337.

15. van Langenberg D. R. et al. The burden of inpatient costs in inflammatory bowel disease and opportunities to optimize care: a single metropolitan Australian center experience. J Crohns Colitis. 2010 Oct; 4 (4): 413-21. DOI: 10.1016/j.crohns.2010.01.004. Epub 2010 Feb 12.

16. Mikocka-Walus A. A. et al. Integrated models of care in managing inflammatory bowel disease: a discussion. Inflamm Bowel Dis. 2012 Aug; 18 (8): 1582-7. DOI: 10.1002/ibd.22877. Epub 2012 Jan 12.

17. Buchanan J. et al. Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers. Journal of Crohn’s and Colitis. 2011; 5 (4): 301-316.

18. Abdulganieva D. I. et al. Clinical and epidemiological indicators of inflammatory diseases of the intestine in the republic of tatarstan. Lechashhij vrach. 2013; 7: 21-26. (in Russ.). eLIBRARY ID: 22474147.

19. Veselov A. V. Inflammatory bowel diseases in the Russian Federation: problems of the regulatory framework and their solutions. According to the materials of the on-site meeting of the Expert Council on Healthcare, the Committee of the Federation Council on Social Policy on the topic “Regulatory and legal improvement in the provision of medical care to patients with inflammatory bowel diseases”. Kazan. 2018. (in Russ.).

20. The Council of the Federation discussed the provision of medical care to patients with inflammatory bowel disease. Vol. 2018, 21.06. [Electronic resource]. URL: http://council.gov.ru/events/news/68074/. Accessed: 11.01.2019.

21. The collection of materials of the meeting of the expert council on health of the Committee of the Federation Council on social policy on the theme “Improving the provision of medical care to patients with inflammatory bowel diseases”. Moscow. 2016; 77 p.

22. Council of Federation Committee on Social Policy. Meeting of the Expert Council on Health. May 19, 2016; Vol. 2018, 19.05. [Electronic resource]. URL: http://social.council.gov.ru/activity/activities/expert_activities/70398/. Accessed: 11.01.2019.

23. Tariff agreement on payment for medical care under the Territorial Compulsory Medical Insurance Program of the Republic of Tatarstan for 2018. [Electronic resource]. URL: http://www.fomsrt.ru/documents/rt/other. Accessed: 11.01.2019.

24. State registry of drugs. [Electronic resource]. URL: https://grls.rosminzdrav.ru/grls.aspx. Accessed: 11.01.2019.

25. Sack C. et al. A chronic care model significantly decreases costs and healthcare utilisation in patients with inflammatory bowel disease. J Crohns Colitis. 2012 Apr; 6 (3): 302-10. DOI: 10.1016/j.crohns.2011.08.019. Epub 2011 Oct.


For citation:


Bezdenezhnykh T.P., Fedyaev D.V., Khachatryan G.R., Arutyunov G.G., Gerasimova K.V. Economic consequences of healthcare optimization for IBD patients in the Republic of Tatarstan. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2019;12(1):14-26. (In Russ.) https://doi.org/10.17749/2070-4909.2019.12.1.14-26

Views: 175


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)